Ensysce Biosciences, Inc. (ENSC) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the NCIS Biosciences, Inc. Corporate Update Call. As a reminder, this conference call is being recorded. Your hosts today are Dr. Lynn Kirkpatrick, Chief Executive Officer, Dr. Bill Smith, Chief Medical Officer, and Dave Humphrey, Chief Financial Officer. Before we begin the phone presentation, I would like to remind everyone that the statements made on the call and webcast may include predictions, estimates, or other information that might be considered forward-looking While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. We are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent forms, 10Q and 10K, for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. At this time, I'd like to turn the call over to Chief Executive Officer, Dr. Lynn Kirkpatrick. Lynn? Thank you, Operator, and good morning, everyone. Thank you for joining us. I am pleased to welcome you to today's corporate update conference call. 2023 was a year of exceptional clinical progress for our next generation analgesics as we move our programs toward commercialization. Before I get into the full background of the company, I remin...